PAXISTA Tablet is an investigational antiviral therapy designed for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients aged 12 years and older weighing over 40 kg who test positive for the SARS-CoV-2 virus. This emergency-use authorized medication is particularly indicated for patients at high risk of disease progression, including hospitalization or death.
The tablet combines Nirmatrelvir 150 MG and Ritonavir 100 MG, where Ritonavir acts as a pharmacokinetic enhancer. By increasing systemic concentrations and prolonging the half-life of Nirmatrelvir, Ritonavir supports a twice-daily dosing regimen, optimizing antiviral effectiveness. PAXISTA Tablet provides a safe and effective approach to managing COVID-19 in high-risk patients, offering a crucial tool in reducing severe outcomes from the infection.
Available for online purchase, PAXISTA Tablet ensures timely access to treatment for eligible patients under medical supervision, helping combat COVID-19 efficiently and safely.